Gary Charles Robb Corcept Therapeutics Inc (CORT) insider trading activity

Gary Charles Robb is Chief Business Officer of CORCEPT THERAPEUTICS INC. Currently has a direct ownership of 22,772 shares of CORT, which is worth approximately $1.12 Million. The most recent transaction as insider was on Oct 01, 2024, when has been sold 11,000 shares (Common Stock) at a price of $46.28 per share, resulting in proceeds of $509,080. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 22.8K

13.38% 3M change

3.53% 12M change

Total Value Held $1.12 Million

Gary Charles Robb Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 01 2024	SELL Open market or private sale	$509,080 $46.28 p/Share	11,000 Reduced 32.57%	22,772 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	$36,190 $3.29 p/Share	11,000 Added 24.57%	33,772 Common Stock
Sep 18 2024	SELL Bona fide gift	-	870 Reduced 3.68%	22,772 Common Stock
Sep 17 2024	SELL Bona fide gift	-	300 Reduced 1.25%	23,642 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$8,966 $35.3 p/Share	254 Reduced 1.1%	22,936 Common Stock
Sep 03 2024	BUY Grant, award, or other acquisition	$17,232 $17.13 p/Share	1,006 Added 4.03%	23,942 Common Stock
Aug 26 2024	SELL Open market or private sale	$110,736 $35.71 p/Share	3,101 Reduced 11.79%	23,190 Common Stock
Jul 01 2024	SELL Open market or private sale	$357,390 $32.49 p/Share	11,000 Reduced 29.5%	26,291 Common Stock
Jul 01 2024	BUY Exercise of conversion of derivative security	$36,190 $3.29 p/Share	11,000 Added 22.78%	37,291 Common Stock
Jun 24 2024	SELL Bona fide gift	-	2,650 Reduced 9.16%	26,291 Common Stock
Jun 04 2024	SELL Payment of exercise price or tax liability	$268,679 $32.87 p/Share	8,174 Reduced 22.02%	28,941 Common Stock
Jun 04 2024	BUY Exercise of conversion of derivative security	$46,060 $3.29 p/Share	14,000 Added 27.39%	37,115 Common Stock
Jun 03 2024	SELL Payment of exercise price or tax liability	$21,843 $30.17 p/Share	724 Reduced 3.58%	19,479 Common Stock
Jun 03 2024	BUY Grant, award, or other acquisition	$56,903 $15.65 p/Share	3,636 Added 13.59%	23,115 Common Stock
May 28 2024	SELL Open market or private sale	$334,290 $30.39 p/Share	11,000 Reduced 35.25%	20,203 Common Stock
May 28 2024	BUY Exercise of conversion of derivative security	$36,190 $3.29 p/Share	11,000 Added 26.06%	31,203 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$15,783 $24.06 p/Share	656 Reduced 3.37%	18,809 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	$16,769 $12.03 p/Share	1,394 Added 6.45%	20,203 Common Stock
Dec 15 2023	SELL Bona fide gift	-	750 Reduced 3.51%	20,640 Common Stock
Dec 06 2023	SELL Open market or private sale	$167,786 $27.01 p/Share	6,212 Reduced 22.51%	21,390 Common Stock
Dec 05 2023	SELL Open market or private sale	$36,278 $26.27 p/Share	1,381 Reduced 4.76%	27,602 Common Stock
Dec 04 2023	SELL Payment of exercise price or tax liability	$230,772 $26.26 p/Share	8,788 Reduced 23.27%	28,983 Common Stock
Dec 04 2023	BUY Exercise of conversion of derivative security	$49,350 $3.29 p/Share	15,000 Added 28.42%	37,771 Common Stock
Dec 01 2023	BUY Grant, award, or other acquisition	$16,575 $12.99 p/Share	1,276 Added 5.31%	22,771 Common Stock
Sep 19 2023	SELL Open market or private sale	$163,700 $32.74 p/Share	5,000 Reduced 18.52%	21,996 Common Stock

GCR

Gary Charles Robb

Chief Business Officer

Menlo Park, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CORT shares.

Notify only if

Value

Insider Trading

Get notified when an Corcept Therapeutics Inc insider buys or sells CORT shares.

Notify only if

Operation

Value

Type

News

Receive news related to CORCEPT THERAPEUTICS INC

Track Activities on CORT

Account